Mark Drayson
Overview
Explore the profile of Mark Drayson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agarwal G, Moore S, Sadler R, Varghese S, Turner A, Chen L, et al.
Haematologica
. 2024 Jan;
109(6):1960-1965.
PMID: 38268439
No abstract available.
2.
Drayson M, Jennis T, Laketic-Ljubojevic I, Patel D, Pratt G, Renwick S, et al.
Br J Haematol
. 2024 Jan;
204(2):476-486.
PMID: 38168756
Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities and early deaths. This delay is largely because the...
3.
Twumasi C, Moore S, Sadler R, Jeans S, Varghese S, Turner A, et al.
Eur J Haematol
. 2023 Dec;
112(4):547-553.
PMID: 38116695
Objective: To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma. Methods: This is a prospective, observational study utilising the RUDYstudy.org...
4.
Campling J, Vyse A, Liu H, Wright H, Slack M, Reinert R, et al.
Expert Rev Vaccines
. 2023 Sep;
22(1):785-800.
PMID: 37694398
Introduction: Pneumococcal disease (PD) significantly contributes to morbidity and mortality, carrying substantial economic and public health burden. This article is a targeted review of evidence for pneumococcal vaccination in the...
5.
Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F
Br J Haematol
. 2023 Aug;
202(4):734-744.
PMID: 37587091
This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal...
6.
Blakey H, Sun R, Xie L, Russell R, Sarween N, Hodson J, et al.
Pregnancy Hypertens
. 2023 Apr;
32:43-49.
PMID: 37088032
Objectives: Pre-eclampsia (PE) is a leading cause of obstetric morbidity, with no definitive therapy other than delivery. We aimed to compare complement markers in maternal and fetal circulation, and placental...
7.
Porteous A, Gibson S, Eddowes L, Drayson M, Pratt G, Bowcock S, et al.
Value Health Reg Issues
. 2023 Feb;
35:27-33.
PMID: 36841011
Objectives: Patients with myeloma often face significant diagnostic delay, with up to one-third of UK patients diagnosed after an emergency presentation (EP). Compared with other routes, patients presenting as an...
8.
Behrens J, Gaskin G, Iggo N, Barratt J, Tighe J, Soutar R, et al.
EJHaem
. 2023 Feb;
4(1):246-250.
PMID: 36819186
Myeloma patients presenting with renal failure continue to have a poor prognosis despite significant advances in anti-myeloma therapy. MERIT was a randomised clinical trial (RCT), set up to evaluate if...
9.
Panopoulou A, Cairns D, Holroyd A, Nichols I, Cray N, Pawlyn C, et al.
Blood
. 2022 Dec;
141(14):1666-1674.
PMID: 36564045
Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in patients in the...
10.
Ramasamy K, Iqbal G, Brouwer R, Stalker V, Akhtar S, Varghese S, et al.
Blood Cancer J
. 2022 Nov;
12(11):162.
PMID: 36446771
No abstract available.